<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03062319</url>
  </required_header>
  <id_info>
    <org_study_id>ATIS-NVAF</org_study_id>
    <nct_id>NCT03062319</nct_id>
  </id_info>
  <brief_title>Optimal Antithrombotic Therapy in Ischemic Stroke Patients With Non-Valvular Atrial Fibrillation and Atherothrombosis</brief_title>
  <acronym>ATIS-NVAF</acronym>
  <official_title>Optimal Antithrombotic Therapy in Ischemic Stroke Patients With Non-Valvular Atrial Fibrillation and Atherothrombosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cerebral and Cardiovascular Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Network for Clinical Stroke Trials</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The BMS/Pfizer Japan Thrombosis Investigator Initiated Research Program</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cerebral and Cardiovascular Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Purpose of this open-label randomized controlled multicenter trial is to evaluate the
      efficacy and safety of mono-drug therapy with oral anticoagulant compared to combination
      therapy with antiplatelet drug, in ischemic stroke patients with non-valvular atrial
      fibrillation and atherothrombosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Purpose of this open-label randomized controlled multicenter trial is to evaluate the
      efficacy and safety of mono-drug therapy with oral anticoagulant compared to combination
      therapy with antiplatelet drug, in ischemic stroke patients with non-valvular atrial
      fibrillation and atherothrombosis. Target sample size is 400. The primary outcome is a
      composite endpoint of ischemic cardiovascular events (cardiovascular death, ischemic stroke,
      myocardial infarction, systemic embolism, ischemic events requiring urgent revascularization)
      and major bleeding defined by the International Society on Thrombosis and Haemostasis(ISTH)
      criteria within 2 years after randomization.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 6, 2017</start_date>
  <completion_date type="Anticipated">January 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite endpoint of ischemic cardiovascular events and major bleeding</measure>
    <time_frame>2 years after randomization</time_frame>
    <description>One of the following ischemic cardiovascular events (cardiovascular death, ischemic stroke, myocardial infarction, systemic embolism, or ischemic events requiring urgent revascularization), or major bleeding defined by the International Society on Thrombosis and Haemostasis (ISTH) criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>2 years after randomization</time_frame>
    <description>All-cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemic cardiovascular events</measure>
    <time_frame>2 years after randomization</time_frame>
    <description>Ischemic cardiovascular events (cardiovascular death, ischemic stroke, myocardial infarction, systemic embolism, ischemic events requiring urgent revascularization)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All ischemic cardiovascular events including transient ischemia</measure>
    <time_frame>2 years after randomization</time_frame>
    <description>All ischemic cardiovascular events including transient ischemia (cardiovascular death, ischemic stroke, transient ischemic attack (TIA), myocardial infarction, unstable angina pectoris, systemic embolism, progression of symptomatic peripheral artery disease, ischemic events requiring urgent revascularization)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemic stroke</measure>
    <time_frame>2 years after randomization</time_frame>
    <description>Ischemic stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction and cardiovascular death</measure>
    <time_frame>2 years after randomization</time_frame>
    <description>Myocardial infarction and cardiovascular death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>major bleeding</measure>
    <time_frame>2 years after randomization</time_frame>
    <description>major bleeding defined by the International Society on Thrombosis and Haemostasis (ISTH) criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intracranial hemorrhage</measure>
    <time_frame>2 years after randomization</time_frame>
    <description>Intracranial hemorrhage</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Ischemic Stroke</condition>
  <condition>Atrial Fibrillation</condition>
  <condition>Atherothrombosis</condition>
  <arm_group>
    <arm_group_label>Dual-therapy group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dual-therapy group: single anticoagulant drug and single antiplatelet drug. The dosage is determined according to each drug's package insert in Japan. In patients treated with warfarin, the target international normalized ratio (INR) range of 2.0-3.0 for those &lt;70 years and 1.6-2.6 for those =&gt;70 years is recommended according to the Japanese guidelines.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single-therapy group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single-therapy group: single anticoagulant drug. The dosage is determined according to each drug's package insert in Japan. In patients treated with warfarin, the target international normalized ratio (INR) range of 2.0-3.0 for those &lt;70 years and 1.6-2.6 for those =&gt;70 years is recommended according to the Japanese guidelines.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Anticoagulant</intervention_name>
    <description>warfarin, dabigatran, rivaroxaban, apixaban, or edoxaban</description>
    <arm_group_label>Dual-therapy group</arm_group_label>
    <arm_group_label>Single-therapy group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antiplatelet Drug</intervention_name>
    <description>aspirin, clopidogrel, prasugrel, ticlopidine, or cilostazol</description>
    <arm_group_label>Dual-therapy group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with an acute ischemic stroke or TIA from 8 days and up to 360 days from the
             onset of symptoms

          2. Age: 20-90 years.

          3. Patients with non-valvular atrial fibrillation (chronic or paroxysmal) who start or
             continue taking an oral anticoagulant

          4. Patients who have one of the following atherothrombotic diseases

               1. A past history of ischemic heart disease (myocardial infarction, angina pectoris,
                  coronary artery bypass graft (CABG), percutaneous coronary intervention (PCI)

               2. A past history of peripheral artery disease (symptomatic peripheral arterial
                  occlusive disease, lower extremity bypass surgery/angioplasty/stenting)

               3. Carotid artery stenosis (symptomatic or asymptomatic (=&gt;50% diameter), a history
                  of carotid artery stenting (CAS) or carotid endarterectomy (CEA))

               4. Intracranial artery stenosis (=&gt;50% stenosis of the diameter of a major
                  intracranial artery: intracranial internal carotid artery, anterior cerebral
                  artery (ACA)-A1 and A2, middle cerebral artery (MCA)-M1 and M2, posterior
                  cerebral artery (PCA)-P1 and P2, vertebral artery, and basilar artery; a history
                  of intracranial stent placement or intracranial bypass surgery)

               5. A past history of atherothrombotic brain infarction, lacunar infarction, or
                  branch atheromatous disease

          5. Patients who can walk independently (modified Rankin Scale score =&lt;3)

          6. Patients who can take oral medications

          7. Patients who can receive follow-up survey

          8. Provision of written informed consent either directly or by a suitable surrogate

        Exclusion Criteria:

          1. History of myocardial infarction or acute coronary syndrome within the past 12 months

          2. Patients who underwent PCI with drug-eluting stents within the past 12 months or PCI
             with bare-metal stents within the past 3 months

          3. Patients who underwent carotid artery stent placement, intracranial stent placement,
             or lower extremity stent placement within the past 3 months

          4. History of symptomatic intracranial hemorrhage or gastrointestinal bleeding within the
             past 6 months

          5. Hemorrhagic diathesis or blood coagulation disorders

          6. Platelet counts &lt;100,000 /mm3 at enrollment.

          7. Severe anemia (hemoglobin &lt;7 g/dL)

          8. Severe renal failure (creatinine clearance =&lt;15 mL/min) or undergoing chronic
             hemodialysis.

          9. Severe liver dysfunction (Grade B or C of the Child-Pugh classification)

         10. Patients who are unable to walk independently (modified Rankin Scale score =&gt;4)

         11. Pregnant or possibly pregnant women

         12. Active cancer

         13. Expectation of survival less than 2 years

         14. Anticoagulant or antiplatelet is scheduled to be discontinued for more than 4 weeks
             during the follow-up period

         15. Planned revascularization procedure during the follow-up period

         16. Patients who are enrolled in other trials

         17. Patients judged as inappropriate for this study by investigators
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hiroshi Yamagami, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cerebral and Cardiovascular Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hiroshi Yamagami, MD</last_name>
    <phone>+81-6-6833-5012</phone>
    <phone_ext>8025</phone_ext>
    <email>yamagami-brain@umin.ac.jp</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shuhei Okazaki, MD</last_name>
    <phone>+81-6-6833-5012</phone>
    <phone_ext>8123</phone_ext>
    <email>s-okazaki@umin.ac.jp</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kobe City Medical Center General Hospital</name>
      <address>
        <city>Kobe</city>
        <state>Hyogo</state>
        <zip>650-0047</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nobuyuki Sakai, MD</last_name>
      <phone>078-302-7537</phone>
      <email>n.sakai@siren.ocn.ne.jp</email>
    </contact>
    <contact_backup>
      <last_name>Nobuyuki Ohara, MD</last_name>
      <phone>078-302-7537</phone>
      <email>nobuyuki.ohara@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>National Cerebral and Cardiovascular Center</name>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <zip>565-8565</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hiroshi Yamagami, MD</last_name>
      <phone>06-6833-5012</phone>
      <phone_ext>8025</phone_ext>
      <email>yamagami-brain@umin.ac.jp</email>
    </contact>
    <contact_backup>
      <last_name>Shuhei Okazaki, MD</last_name>
      <phone>06-6833-5012</phone>
      <phone_ext>8123</phone_ext>
      <email>s-okazaki@umin.ac.jp</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 8, 2017</study_first_submitted>
  <study_first_submitted_qc>February 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2017</study_first_posted>
  <last_update_submitted>December 22, 2017</last_update_submitted>
  <last_update_submitted_qc>December 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Cerebral and Cardiovascular Center</investigator_affiliation>
    <investigator_full_name>Hiroshi Yamagami</investigator_full_name>
    <investigator_title>Head Physician, Division of Stroke Care Unit</investigator_title>
  </responsible_party>
  <keyword>anticoagulant</keyword>
  <keyword>antiplatelet</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Anticoagulants</mesh_term>
    <mesh_term>Platelet Aggregation Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

